Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor
13. Dezember 2024 09:45 ET
|
Curative Biotechnology, Inc.
Palm Beach Gardens, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel...
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
31. März 2024 19:00 ET
|
Curative Biotechnology, Inc.
Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company...
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
22. März 2024 09:45 ET
|
Curative Biotechnology, Inc.
Palm Beach Gardens, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel...
Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome
06. April 2023 08:01 ET
|
Ocean Biomedical, Inc.
On Hermansky-Pudlak Syndrome (HPS) Awareness Day, Ocean Biomedical announces a commitment to developing viable treatment options for HPS-1 and HPS-4 Providence, RI, April 06, 2023 ...
[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
24. November 2021 15:05 ET
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
24. November 2021 10:00 ET
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”
29. April 2021 10:12 ET
|
Curative Biotechnology, Inc.
Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board Boca Raton, FL, April 29, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) a...
Connectyx Reports Fiscal Year 2020 Financial Results
09. März 2021 10:24 ET
|
Connectyx Technologies Holdings Group, Inc
Biotechnology Company Issues Highlights and Subsequent Events Boca Raton, Fla, March 09, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the...
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma
16. Oktober 2020 11:00 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...